Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc)

New study finds that mRNA vaccination sustained influenza-specific germinal-center activity for up to six months in some participants SEOUL, South Korea, Sept. 11, 2026 /PRNewswire/ -- Influenza remains a major global health challenge as continual antigenic drift can limit the breadth and durability of vaccine-induced antibody responses, requiring frequent vaccine updates. Researchers are therefore seeking strategies to generate broader, longer-lasting protection. A key focus is the germinal-center (GC), where B cells undergo selection and somatic hypermutation to produce diverse, high-affinity antibodies and long-lived memory B cells. Continue Reading Sustained germinal-center activity may help diversify antibody responses against evolving influenza strains Researchers from Korea University College of Medicine, Republic of Korea, led by Associate Professor Jiwon Lee in the Department of Convergence Medicine and Vaccine Innovation Center, investigated whether an mRNA influenza vaccine could stimulate stronger and more persistent GC responses than a conventional split-virion vaccine, potentially broadening antibody recognition. The study was conducted with Professor Ali Ellebedy and his group at Washington University in St. Louis, USA. The study evaluated the investigational quadrivalent mRNA-1010 vaccine against the licensed Fluarix vaccine and was published in Nature Immunology on June 15, 2026. The study followed 75 healthy adults aged 20–50 years across two influenza seasons, with 38 receiving mRNA-1010 and 37 receiving Fluarix. Blood samples were collected through 26 weeks, while a subset underwent ultrasound-guided fine-needle aspiration of draining axillary lymph nodes to assess germinal-center responses. Researchers combined flow cytometry, ELISpot, single-cell RNA sequencing and B-cell receptor sequencing, serum IgG proteomics, and antibody binding and neutralization assays to comprehensively profile immune responses. Dr. Lee explains, "We found that the mRNA vaccine elicited a substantially more diverse and broader serum antibody repertoire than Fluarix." Most notably, influenza-specific GC responses persisted for up to 26 weeks in 5 of 13 mRNA-1010 recipients, while persistent GCs were not detected among Fluarix recipients. The vaccine increased the diversity of the serum IgG repertoire and promoted diversification of pre-existing B-cell lineages through somatic hypermutation. These changes were associated with broader antibody binding across antigenically diverse influenza strains and greater increases in neutralization titers against 11 of 13 A/H1N1 viruses tested. Dr. Lee adds, "The mRNA platform does not simply produce more antibodies, it produces a more diversified antibody response, which leads to greater binding and neutralizing breadth." A key strength of the study was Ig-Seq, a mass-spectrometry-based technology that identifies individual antibody clonotypes circulating in the blood after vaccination. Dr. Lee notes, "Conventional vaccine studies typically measure the bulk binding or neutralization titers, but Ig-Seq allows us to resolve that response down to individual antibody clonotypes." Together with B-cell sequencing, this molecular-level approach revealed not only the magnitude of the antibody response, but also which antibody lineages emerged, expanded, and diversified after vaccination. The authors identify Ig-Seq as a key strength of the study because it provides molecular-level information that conventional bulk antibody measurements cannot capture. The study highlights the potential of mRNA technology to generate broader, more durable influenza immunity by sustaining GC activity and supporting continued B-cell evolution. Further studies are needed to determine whether these responses translate into multi-season protection or longer vaccination intervals. Future research should also investigate whether these benefits are maintained in older adults and immunocompromised populations, whose immune responses may differ from those of healthy younger adults. Ultimately, persistent GC responses and molecular tools such as Ig-Seq could help guide the development of influenza vaccines designed to generate broader antibody responses against an evolving virus. Reference Title of original paper: mRNA-based influenza vaccine expands the B cell response breadth in humans Journal: Nature Immunology DOI: About Korea University College of Medicine Website: Media Contact Soo-Jin Jeon +82 2 3407 4040 [email protected] SOURCE Korea University College of Medicine 21% more press release views with Request a Demo

Osivax has licensed an influenza vaccine from GC Biopharma, positioning the biotech to build on early evidence that its midphase candidate complements traditional flu shots. France’s Osivax will lead development of a combination vaccine candidate that pairs its OVX836 with the newly licensed GC FLU. OVX836 is an influenza A vaccine candidate that targets the nucleoprotein (NP), a highly conserved internal antigen. GC FLU is an inactivated seasonal influenza vaccine designed to trigger antibody responses against hemagglutinin surface antigens from A and B forms of the flu virus. Osivax has secured a non-exclusive license to GC FLU outside of Japan and Korea. The French biotech will be responsible for development and commercialization of the combination vaccine outside of Korea, GC Biopharma’s home market. GC Biopharma will supply its vaccine and receive royalties. The vaccine combination reflects evidence that adding OVX836 to a traditional flu vaccine could broaden protection against influenza A. Vaccines such as GC FLU induce antibody responses against proteins on the surface of flu viruses. Because the prevalent surface proteins change over time, manufacturers need to update vaccines for each season and even then only partly hit the moving target, diminishing efficacy. The NP targeted by OVX836 is well-conserved across influenza A strains. Using OVX836 to trigger a T-cell response against NP could complement the antibody responses caused by conventional vaccines, making a combination more effective than either shot in isolation. Osivax generated early evidence to support that idea in a phase 2a study that tested OVX836 with GSK’s Fluarix Tetra. The biotech came away from the trial, which enrolled 60 healthy volunteers, believing that synergistic immune responses and broader cross-protection could make the combination more effective than current monotherapy vaccines. Osivax also tested the combination in a larger phase 2 study. Participants in the combination trials have received separate injections of OVX836 and Fluarix Tetra. The potential for co-administration to depress vaccination rates, especially among people afraid of needles, led Osivax to seek to develop a single shot that combines OVX836 with an inactivated influenza vaccine. The GC Biopharma deal gives Osivax the building blocks of the combination vaccine.